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The quality of healthcare, particularly as reflected in current practice versus the available
evidence, has become a major focus of national health policy discussions. Key components
needed to provide quality care include: 1) development of quality indicators and performance
measures from specific practice guidelines, 2) better ways to disseminate such guidelines and
measures, and 3) development of support tools to promote standardized practice. Although
rational decision-making and development of practice guidelines have relied upon results of
randomized trials and outcomes studies, not all questions can be answered by randomized
trials, and many treatment decisions necessarily reflect physiology, intuition, and experience
when treating individuals. Debate about the role of “evidence-based medicine” also has raised
questions about the value of applying trial results in practice, and some skepticism has arisen
about whether advocated measures of clinical effectiveness, the basic definition of quality,
truly reflect a worthwhile approach to improving medical practice. We provide a perspective
on this issue by describing a model that integrates quantitative measurements of quality and
performance into the development cycle of existing and future therapeutics. Such a model
would serve as a basic approach to cardiovascular medicine that is necessary, but not sufficient,
to those wishing to provide the best care for their patients. (J Am Coll Cardiol 2002;40:
1895–901) © 2002 by the American College of Cardiology Foundation
The quality of medical care has become a major focus of
health policy discussions, especially since publication of the
Institute of Medicine reports on medical errors (1) and
quality gaps (2). These reports describe the wide, deep gulf
separating current evidence from current practice. They also
outline key components needed to provide quality care:
development of quality standards based on specific practice
guidelines, better ways to disseminate such guidelines and
standards to the public and providers, and development of
information technology and other support tools to promote
standard practice. To enhance progress in this effort, prac-
titioners must understand the quantitative and qualitative
concepts involved in quality improvement.
DEFINITION OF QUALITY AND
THE ROLE OF CLINICAL TRIALS
Quality in medicine can be defined as how much health
services increase the likelihood of desired health outcomes
and how closely they adhere to professional knowledge (3).
The Rand Institute defines quality care as “providing
patients with appropriate services in a technically competent
manner, with good communications, shared decision-
making, and cultural sensitivity” (4). Along with safety and
efficacy, the Institute of Medicine considers patient-
centered activities (responsiveness to individual preferences
and needs), timeliness, efficiency, and equitable resource use
to be critical to quality healthcare. However, although these
elements are important, medicine must above all provide
safe and effective use of diagnostic and therapeutic technol-
ogies, or clinical effectiveness, for the rest to have meaning.
Randomized trial and outcome studies have provided a
basis for informed decisions about the use of medical
technologies. Randomized trials cannot answer all ques-
tions, however, and many decisions in practice must be
made based on an understanding of physiology, intuition,
and experience when treating individuals. Questions have
also arisen about the value of applying randomized trials in
clinical practice, with skepticism about whether advocated
measures of clinical effectiveness truly reflect a worthwhile
approach to improving medical practice.
We provide a perspective on this issue by presenting a
model that integrates quantitative measurements of quality
and performance into the development cycle for therapeu-
tics. Such a model could serve as a basic approach to
cardiovascular medicine that is necessary, but not sufficient,
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to those wishing to provide the best care for their patients.
These concepts have evolved largely through ongoing efforts
of the American College of Cardiology (ACC) and Amer-
ican Heart Association (AHA) to develop clinical practice
guidelines (CPGs) and performance indicators for cardiol-
ogy, but the issues raised in this review pertain to all areas of
medicine.
INTEGRATION OF QUALITY
IN THE DEVELOPMENT CYCLE
We present a model to integrate quality measures into the
development cycle for therapeutics, adapted from a previous
concept, the “great circle” (Fig. 1) (5). There are six main
“stops” along the circle, each representing a chance to apply
quantitative strategies to integrate quality.
To summarize the circle, first, hypotheses (Concepts)
evolve from biological discoveries or clinical observations.
These include proposed mechanisms of disease, diagnostic
technologies, or therapeutics that emerge from basic and
animal research. After these concepts are refined, they are
tested in various phases of Clinical Research (randomized
trials and outcomes studies). Initial clinical research pro-
duces “proof of principle” and preliminary safety data,
whereas large, representative trials measure the clinical
benefits and risks of technologies. The latter form of clinical
research provides the highest-level evidence for the creation
of practice Guidelines.
Recommendations about diagnosis and treatment con-
tained in a given guideline can be synthesized into algo-
rithms, which then can be used as Quality Indicators,
specifying the clinical circumstances under which to use a
technology. By determining how well a provider or institu-
tion meets these quality indicators, actual Performance Mea-
sures can be assessed. The final stage in the cycle then links
measured performance with the ultimate goal of healthcare,
better Outcomes. For all of these elements to contribute
optimally to the overall system, continuous education and
feedback about findings and concepts are needed; thus,
these aspects are in the center of the cycle.
As an example, suppose the preponderance of basic and
clinical evidence leads a CPG to recommend that all eligible
patients receive a beta-adrenergic blocking agent after acute
myocardial infarction (MI). This recommendation could
translate into the quality indicator “prescription for beta-
blocker at discharge after MI.” The corresponding perfor-
mance measure then would be “proportion of eligible
patients prescribed a beta-blocker at discharge after MI.”
Stated simply, the guideline generates a criterion (the
quality indicator), and how well it is met by providers or
institutions is the performance measure.
By studying the links between and among cycle elements,
we might begin to develop ideas for building a quality
system. Of note, this approach deals with only one compo-
nent of quality, although this quantitative component relat-
ing to outcomes may distinguish the medical environment
from other elements affecting healthcare quality. Without
excellence in the subjective element, these quantitative
elements are moot. With this idea of giving care to the
individual patient in mind, several attributes that would
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
CPG  clinical practice guideline
ESC  European Society of Cardiology
MI  myocardial infarction
Figure 1. Model for the integration of quality into the therapeutic development cycle.
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enhance each cycle element become evident, and many
research questions can be posed.
Concepts: biological insights and the treachery of sur-
rogates. Insight into disease mechanisms is essential to
develop concepts for diagnostic and therapeutic products.
Given the accelerating insights from genomics and pro-
teomics, a wealth of biological targets seems probable. Of
more immediate relevance, bioengineering progress is mak-
ing devices and their combinations with drugs or biologics
an increasingly routine part of medicine, as evidenced in
cardiology by the advent of coated stents (6), wider indica-
tions for defibrillators (7,8), and mechanical assist devices
for heart failure (9). Therapies based on genomic and
proteomic technology will soon follow, and diagnostic tests
will eventually use analysis of genetic variations to identify
patients more or less likely to respond to given therapies.
Pressure continues to increase to develop ways to assess
the efficacy and safety of new technologies. Many have
advocated the use of biological “surrogates,” known as
biomarkers, to substitute for clinical outcomes during de-
velopment. Although biomarker results should be consid-
ered when deciding which theories to pursue in trials
(10,11), they provide only an entry point for medical
products. Even therapies that produce substantial benefits
for a respected surrogate may fail because of other safety
problems (12,13). Perhaps most important, although bi-
omarkers may identify particular benefits of therapies, they
cannot reliably reflect the balance between the risks and
benefits of therapies, information critical to determining
their value (14).
The treachery of surrogates has caused cardiovascular
specialists to require large outcomes trials as a basis for the
highest level recommendations in CPGs. Arrays of biomar-
kers are urgently needed, however, to determine when it is
reasonable to invest in such trials. Of note, single biomar-
kers are insufficient for this purpose. Antithrombotic drugs,
for example, can affect markers of thrombin, platelet acti-
vation, and inflammation differently, precluding translation
into a cohesive, quantitative estimate. Imaging methods
provide a promising approach to biomarker evaluation, by
integrating structure and function into a common measure-
ment.
Clinical research: the standard of evidence. Clinical trials
are preferable as the source of evidence whenever possible.
From a regulatory standpoint, a definitive clinical trial must
be “adequate and well controlled” and must assess the safety
and efficacy of a product when used in the intended
population. To be helpful in the qualitative component of
quality, however, a trial also must address the issues of
practicality, applicability, and effectiveness. This means that
a trial should measure clinically relevant outcomes in a
representative population given the treatment in practice for
a clinically relevant duration. “Large, simple trials”—with
minimal data collection and “harnessing” data from elec-
tronic medical records—often can accomplish this goal
(15).
Empirical experience has now provided cardiovascular
practitioners with general principles to consider when de-
signing trials designed to inform the cycle of quantitative
evidence (Table 1) (16). For example, the modest nature of
most treatment effects mandates large trials, so that effects
can be detected or excluded with certainty. Large trials also
can and should enroll a wide variety of patients, so that
quantitative and qualitative interactions can be estimated for
policy reasons. Large trials also maximize the possibility of
detecting unanticipated effects of therapies, alone and com-
bined with other technologies.
Being large is not enough, however. Accurate assessments
of effectiveness also require clinically relevant follow-up
periods, given that short-term outcomes may not reliably
predict long-term events (17). Furthermore, most major
cardiovascular diseases already have at least one effective
treatment. The finding that not all therapies in a general
class have the same balance of risk and benefit (18,19), with
inherent uncertainties in combining therapies, mandates
comparative trials. Trials also must consider current CPG
recommendations. For example, a trial of a new secondary
prevention approach that prohibits statin use might be more
likely to show an effect of the experimental agent, but it
would provide no information about whether the new agent
should be preferred over standard treatment (which includes
statins), combined with standard treatment, or substituted
for standard treatment.
Clinicians feel increasingly pressed for time, and financial
constraints leave little room for altruistic efforts to engage
patients in discussions about trials. Questions about the
professional responsibilities of physicians (duty to individual
patients) versus trialists (duty to answer questions), and the
constraints of institutional review boards and consent mech-
anisms, also make the conduct of research in clinical practice
more daunting. The new Health Information Privacy,
Portability, and Accountability Act, which places criminal
penalties on the misuse of medical information, has exac-
erbated these concerns. Nevertheless, cardiovascular medi-
cine has led the way by engaging many practices in address-
ing important questions that cannot be answered by a
separate trials infrastructure (15). Highly organized cardi-
ology practices have been the cornerstone of successful trials
(20,21), and the federal government now reimburses phy-
Table 1. General Principles to Consider in the Design of
Clinical Trials (16)





Short-term effects do not reliably predict long-term effects
Class effect almost impossible to define
Most therapies produce a combination of helpful and harmful effects
Effective therapies do not usually save money, but they are incrementally
cost-effective
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sicians for the routine costs of trials in patients covered by
Medicare (22).
Finally, in many cases randomized trials cannot be per-
formed because: 1) they would be impractical, 2) they would
be unethical, or 3) the follow-up needed would exceed
society’s “willingness to wait.” However, standards for ob-
servational comparisons have not evolved to the same level
as for clinical trials (23). Although newer statistical tech-
niques allow better control of treatment selection in obser-
vational research, unmeasured sources of bias will always be
a concern. Thus, observational studies will continue to
support randomized studies: hypothesis generation, testing
(if randomized trials are impossible), and confirming that
the results of randomized trials can be generalized to other
providers and patient populations.
Clinical practice guidelines: synthesis of evidence. A
hierarchy of evidence forms the basis for formulation of
CPGs. The highest level of evidence reflects large trials
addressing the specific question of interest or several smaller
trials with consistent results. The ACC/AHA guideline for
unstable angina and non–ST-segment elevation MI pro-
vides a framework for considering evidence (24). As shown
in Table 2, evidence can be generated in two vectors,
roughly representing the quantitative and qualitative per-
spectives. A level of evidence of “A” for a recommendation
is derived from multiple, consistent randomized trials or a
single large, definitive trial. A “C” level represents expert
opinion and no definitive data, and a “B” level encompasses
various intermediate-quality data. In the other vector, a class
I recommendation reflects consensus that the practice
should be done, whereas a class III recommendation reflects
consensus that the practice should be avoided. A class IIa
recommendation denotes a situation in which consensus
does not exist but the practice is generally reasonable, and
class IIb recommendation does not endorse the practice but
does not definitively recommend against it.
A recent document from the ACC and AHA provides
insight into the CPG process (24). An obvious first question
is the composition of the guidelines committee. The ACC/
AHA strategy is to select committee members through
consensus of the parent guideline task force and the presi-
dents of the two organizations. Efforts are made to include
representatives from the ACC, AHA, and other profes-
sional organizations and views from different regions, prac-
tices, and organizations within cardiovascular medicine.
Real and potential conflicts of interest (25) are identified at
the outset and reviewed periodically.
In addition to committee composition, review of the
guidelines before finalization is a major issue. Ideally, all of
the affected constituencies should agree with the draft
CPGs. When appropriate, joint ACC/AHA guidelines
typically also are reviewed by the American Academy of
Family Practitioners, the American College of Physicians–
American Society of Internal Medicine, and other major
professional organizations caring for cardiovascular patients.
A recent experimental guideline for atrial fibrillation also
has attempted to reach consensus between the American
organizations and the European Society of Cardiology
(ESC) (26).
Updating the guidelines is another significant component
of the process. In many areas of medicine, trials are being
performed at such a pace that major findings relevant to
clinical practice are common. For example, the Global Use
of Strategies To Open occluded arteries (GUSTO)-IV trial
of acute coronary syndromes (27) was reported within days
of publication of both the ACC/AHA guidelines (24) and
ESC guidelines on unstable angina and non–ST-segment
MI (28). Within months of the publication of the ACC/
AHA guidelines on heart failure (29), a randomized trial (9)
showed a survival advantage for left ventricular assist de-
vices, and initial data from another randomized study (7)
appeared to expand the indications for implantable defibril-
lators. As other areas of clinical practice change, existing
therapies must be reevaluated.
Most current CPGs do not emphasize costs, partly
because information about the cost-effectiveness of thera-
pies is often scant and based on models rather than
empirical data. In theory, best practice is defined by the
quality of evidence for the intervention rather than its price.
The fact that cost does affect therapeutic choice has pro-
duced a crisis, however, as illustrated by the escalation of
healthcare costs versus the increasing imperatives to implant
defibrillators (7,8), coated stents (6), or left ventricular assist
devices (9). These examples suggest that CPGs might need
to be country-specific, depending on national resources. In
the U.S., an incremental cost of $50,000 to $70,000 per year
of life saved has become a de facto standard based on the
national right to dialysis (30), but in many countries, even
when a therapy clearly is beneficial, it simply is unaffordable
given competing demands for financial resources.
Quality indicators. Once a CPG has been developed, its
recommendations must be translated into a series of vari-
ables, or indicators, that reflect the quality of care (or lack
thereof). In an ideal clinical world, for every clinical decision
there would be an indicator based on a guideline based on
evidence from randomized trials, such that a standard of




I Intervention is useful and effective
IIa Evidence conflicts/opinions differ but lean
towards efficacy
IIb Evidence conflicts/opinions differ but lean
against efficacy
III Intervention is not useful/effective and
may be harmful
Level of evidence
A Data from many randomized clinical trials
B Data from single randomized trial or
nonrandomized studies
C Expert consensus
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care could be defined for each situation. Such data exist for
few clinical decisions, however. Table 3 lists the class I, level
A recommendations (“almost always do it”) from the ACC/
AHA guidelines for unstable angina/non–ST-segment ele-
vation MI (24) and heart failure (29). Table 4 lists the class
III, level A recommendations (“never do it”) from these
same guidelines.
Given the small number of definitive recommendations,
it would seem simple to develop quality indicators. The
issue is much more complex, however. For each recommen-
dation, there are exceptions and areas of uncertainty. Given
unlimited space to define exceptions and elaborate on
nuances, CPGs could provide a panoramic translation of
evidence into recommendations. By their nature, however,
quality indicators translate recommendations into measures
that can be defined and quantified in the context of
Table 3. Class I, Level of Evidence A, Recommendations from Selected ACC/AHA Guidelines
Guidelines Recommendation
Acute coronary syndromes (ACS) (24) ● Assessment of patients with definite ACS and ST-segment elevation for immediate reperfusion therapy
● Immediate, continued antiplatelet therapy with aspirin; add clopidogrel as soon as possible, continue
for 1 month (indefinitely if aspirin not tolerated)
● Platelet glycoprotein IIb/IIIa inhibition (plus aspirin and heparin) if continued ischemia or other
high-risk features
● Subcutaneous LMWH or intravenous unfractionated heparin (plus aspirin and/or clopidogrel)
● Platelet glycoprotein IIb/IIIa antagonist (plus aspirin and heparin) if catheterization and PCI planned
● Early invasive strategy for: recurrent angina/ischemia: 1) at rest, 2) with low-level activities despite
intensive anti-ischemic therapy, or 3) with HF symptoms, S3 gallop, pulmonary edema, worsening
rales, or new/worse mitral regurgitation; elevated troponins; new ST-segment depression; high-risk
findings on noninvasive stress testing; left ventricular systolic dysfunction (e.g., ejection fraction 40%
on noninvasive test); hemodynamic instability; sustained ventricular tachycardia; PCI 6 months;
prior bypass surgery
● PCI for multivessel disease with suitable anatomy, normal LV function, and no diabetes
● Bypass surgery for significant left main disease, three-vessel disease, or two-vessel disease with
significant pLAD and either LV dysfunction or ischemia during noninvasive testing
● Lipid-lowering drugs (HMG-CoA reductase inhibitor) and diet if LDL level 130 mg/dl
● Hypertension control to 130/85 mm Hg
● ACEI for patients with HF, ejection fraction 40%, hypertension, or diabetes
● Diabetes is an independent risk factor
Heart failure (HF) (29) ● Overall: revascularization if concurrent angina, anticoagulants if concurrent atrial fibrillation or
thromboembolic event, control of ventricular response with beta-blocker (or amiodarone) if concurrent
atrial fibrillation; beta-blocker in patients with HF to reduce risk of sudden death; implantable
cardioverter-defibrillator (alone or with amiodarone) if prior cardiac arrest or severe ventricular
arrhythmia
● Stage A patients: control of systolic and diastolic hypertension as per guidelines
● Stage B patients: all class I Stage A recommendations, ACEI if prior myocardial infarction,
beta-blocker if recent infarction
● Stage C patients: all class I recommendations from prior stages; diuretics if fluid retention; ACEI,
beta-blocker, digitalis in all patients unless contraindicated
● Stage D patients: all class I recommendations from prior stages, referral to experienced HF program
ACEI  angiotensin-converting enzyme inhibitor; ACC  American College of Cardiology; ACS  acute coronary syndromes; AHA  American Heart Association; HF 
heart failure; LDL  low-density lipoprotein; LMWH  low-molecular-weight heparin; LV  left ventricular; PCI  percutaneous coronary intervention; pLAD  proximal
left anterior descending artery.
Table 4. Class III, Level of Evidence A, Recommendations from Selected ACC/AHA
Guidelines
Guideline Recommendation
Acute coronary syndromes (24) ● Immediate-release dihydropyridine calcium antagonist without
beta-blockade
● Thrombolytic therapy without ST-segment elevation,
left bundle-branch block, or true posterior infarction
● Abciximab if PCI is not planned
Heart failure (29) ● Overall: class I or III antiarrhythmic drugs (except amiodarone)
to prevent or treat asymptomatic ventricular arrhythmia,
ambulatory electrocardiography to detect asymptomatic
ventricular arrhythmia
● Stage C patients: use of an angiotensin-receptor blocker before
beta-blocker in patients taking ACEI
ACC/AHA  American College of Cardiology/American Heart Association; ACEI  angiotensin-converting enzyme
inhibitor; PCI  percutaneous coronary intervention.
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delivering healthcare. This means that their measurement
cannot impede healthcare delivery or require such complex
data collection that it becomes too costly.
Several organizations are implementing quality indicators
and performance measures for cardiovascular care. Many of
the same issues that pertain to construction of CPGs also
apply to development of the resulting quality indicators.
Who should be on the committees and how are conflicts of
interest managed? What level of evidence in a guideline
should merit a quality indicator? How should those who
devise guidelines react when a quality indicator is advocated
that is inconsistent with existing guidelines? The ACC and
AHA have a task force considering this very issue, and a
report is expected very soon.
A particularly vexing problem for quality indicators
emerges when attempting to define which patients qualify
for a particular indicator. For example, when the Coopera-
tive Cardiovascular Project investigators measured the use of
fibrinolytic therapy in patients covered by Medicare, less
than half of the patients with acute MI actually qualified for
measurement after a long list of potential exclusions was
applied (31). Care among such filtered subgroups may not
reflect providers’ general practices.
Performance measures. If the quality indicator is the
variable, the performance measure is the threshold. The
concept is straightforward: in its simplest form, a quality
indicator reflects either a class I, level A recommendation
(use beta-blockers after MI) or a class III, level A recom-
mendation (do not perform routine angioplasty of the
infarct-related artery immediately after fibrinolysis). Each
encounter with a patient who meets the circumstances of
such recommendations provides evidence to assess the
performance of providers or systems. The proportion of
eligible patients with MI who receive beta-blockers, say,
would be compared against some threshold level, or perfor-
mance measure, in this case, perhaps 95%.
This raises the logical question of how thresholds are set.
One attractive approach has been to develop “achievable
benchmarks of care” (32). Instead of attempting to define
purified populations for whom process indicators should
approach 100%, one simply compares a provider’s perfor-
mance to that seen among the top 10% of practitioners,
hospitals, or practices. Thus, if leading centers can prescribe
beta-blockers at discharge for 90% of their patients with
MI, then this would be a reasonable and achievable perfor-
mance goal for the rest of the nation. The Achievable
Benchmark method provides one reasonable approach and
avoids striving for unrealistic goals, which could provoke
practitioners into inappropriate treatment for patients who
do not meet criteria or lead them to become cynical about
efforts to measure quality.
A related issue concerns the number of quality indicators.
Specifically, as the number of quality indicators increases,
the number of performance measures also will rise, creating
a signal-to-noise issue when reviewing these results. Fortu-
nately, process performance is likely to correlate, and centers
that adhere closely to national guidelines on one measure
might tend to do similarly well in other care areas. One also
could develop overall “composite quality indicators” for
given conditions, which combine and average provider
performance on individual measures. Taking into account
multiple measures per patient, composite quality indicators
also increase the power for a given sample size and, thus,
provide more stable estimates of performance.
Given the large number of decisions that providers and
systems make that are not subject to advanced levels of
evidence, it is tempting to define performance in terms of
higher level, complex decision-making. Indeed, most would
agree that healthcare systems must be able to provide
integrated care for patients with multiple comorbidities
requiring complicated procedures and regimens to be con-
sidered “high-quality” systems (i.e., excellent performance).
The argument is equally strong, however, that practitioners
and systems who do not adhere to relatively simple guide-
lines based on clear evidence cannot claim to have even basal
levels of quality (i.e., poor performance).
In developing performance measures, it can be useful to
focus on the specific environment (microenvironment) for
healthcare delivery (31,33). The inpatient cardiovascular
arena, for example, contains the various microenvironments
of the emergency department; cardiac care unit; inpatient
service; cardiac catheterization, interventional, and electro-
physiology laboratories; surgical suite and postoperative
intensive care unit; and noninvasive testing and imaging
systems. The cardiovascular specialist’s and primary care
practitioner’s microenvironments include the practice struc-
ture, office staff, nonphysician practitioners, and systems.
The outpatient arena is even more vast, encompassing the
patient’s home, workplace, various healthcare providers,
social outlets, religious community, and insurance coverage.
By measuring actual outcomes in populations, deviations
from expected results should spur scientific insights, refined
trial designs, and development of more appropriate quality
indicators and performance measures for various settings.
Outcomes. From the perspective of the quality cycle, the
ultimate goal is the best possible outcomes. Fortunately for
cardiovascular practitioners, there is consensus about the
outcome domains that are generally most important to the
field, and these have been validated in many trials and
observational studies. For most cardiovascular problems,
survival, freedom from major cardiovascular events (stroke,
MI, major arrhythmias, heart failure), and improved symp-
toms are the cornerstones of outcomes measurement. Much
research also has focused on measurement of functional
outcomes and quality of life in cardiovascular patients.
Ideally, outcome measures would assess both the acute
success of an episode of medical care and its long-term
effects.
Outcomes measurement also faces particular challenges,
however. These include how to adjust for patient risk
(disease severity, comorbidity, educational, and financial
status) when comparing outcomes among providers and the
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instability of outcome measures at the provider level. Be-
cause of these limitations, the quality-assessment field has
moved from direct measurement of outcomes to measure-
ment of performance in most situations. As mentioned,
because performance measures are essentially surrogates, the
quality cycle calls for studies of the broader measurement of
outcome as a function of performance in populations of
patients or practitioners, to validate that the performance
measures are important and that greater adherence to them
improves outcome.
Recommendations. Clinical research networks and prac-
tice databases provide a convenient mechanism to tie to-
gether the quality cycle (Fig. 1). After a concept has been
developed and undergone basic testing, a network could
conduct clinical trials and measure incorporation of the
findings (in the form of recommendations) into practice.
Multiple practice registries can provide feedback about perfor-
mance for individual practices while also validating the relation
between greater adherence to guidelines (in the form of
performance measures) and improved patient outcomes in the
registry as a whole. In the process, new concepts would be
developed that can then be tested, beginning the cycle anew.
Finally, education and feedback, though inadequate to improve
processes and outcomes, remain a necessary foundation for all
elements of the cycle.
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